(NASDAQ: OVID) Ovid Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Ovid Therapeutics's earnings in 2026 is -$17,414,000.On average, 13 Wall Street analysts forecast OVID's earnings for 2026 to be -$58,064,401, with the lowest OVID earnings forecast at -$84,004,142, and the highest OVID earnings forecast at -$47,079,244. On average, 10 Wall Street analysts forecast OVID's earnings for 2027 to be -$65,330,694, with the lowest OVID earnings forecast at -$95,635,485, and the highest OVID earnings forecast at -$47,079,244.
In 2028, OVID is forecast to generate -$83,806,330 in earnings, with the lowest earnings forecast at -$115,021,056 and the highest earnings forecast at -$56,772,030.